JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on March 12, 2004; DOI: 10.1124/jpet.103.063925


0022-3565/04/3101-376-385$20.00
JPET 310:376-385, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.063925v1
310/1/376    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeong, E. J.
Right arrow Articles by Hu, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeong, E. J.
Right arrow Articles by Hu, M.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Disposition Mechanisms of Raloxifene in the Human Intestinal Caco-2 Model

Eun Ju Jeong, Huimin Lin, and Ming Hu

Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Pullman, Washington

The purpose of this study was to determine the mechanisms responsible for transport of raloxifene and its hydrophilic conjugates. Human intestinal Caco-2 cell culture model and Caco-2 cell lysate were used for the studies. The results indicated that absorptive permeability (PAB) of raloxifene was lower than its secretory permeability (PAB). As the concentration increased, the efflux ratio (PBA/PAB) decreased, but PBA increased. PAB was also increased in the presence of verapamil and cyclosporine A, two P-glycoprotein inhibitors. Raloxifene was extensively metabolized into sulfated and glucuronidated conjugates. The extent of metabolism or clearance was decreased as the concentration increased from 3.4 (96%) to 30 (22%) µM. Multidrug resistance-related protein inhibitors MK-571 (C26H26ClN2O3S2) and leukotriene C4 significantly de creased (maximal 80%) apical efflux of both conjugates. They also significantly decreased (maximal 85%) basolateral efflux of glucuronides but not sulfates. On the other hand, organic anion transporter (OAT) inhibitor estrone sulfate and estrone glucuronide significantly decreased (maximal 50%) the efflux of sulfate from both sides but had variable effects on glucuronide efflux. Inhibition of conjugate efflux with the OAT inhibitor estrone sulfate was concentration dependent, which resulted in increased transport of intact raloxifene (maximal 90%). This increase in raloxifene transport was also observed in the presence of another OAT inhibitor estrone glucuronide (70%). In conclusion, this is the first report that inhibition of an efflux transporter responsible for the transport of metabolites can result in increase in the transport of the intact compound. It also provides additional explanation why raloxifene has low bioavailability but a long half-life.


Received December 5, 2003; accepted March 11, 2004.

Address correspondence to: Dr. Ming Hu, Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Pullman, WA 99164-6510. E-mail: minghu{at}wsu.edu




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
J. H. Chang, C. J. Kochansky, and M. Shou
The Role of P-glycoprotein in the Bioactivation of Raloxifene
Drug Metab. Dispos., December 1, 2006; 34(12): 2073 - 2078.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. W. J. Wang, J. Chen, X. Jia, V. H. Tam, and M. Hu
Disposition of Flavonoids via Enteric Recycling: Structural Effects and Lack of Correlations between in Vitro and in Situ Metabolic Properties
Drug Metab. Dispos., November 1, 2006; 34(11): 1837 - 1848.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. L. Falany, D. E. Pilloff, T. S. Leyh, and C. N. Falany
SULFATION OF RALOXIFENE AND 4-HYDROXYTAMOXIFEN BY HUMAN CYTOSOLIC SULFOTRANSFERASES
Drug Metab. Dispos., March 1, 2006; 34(3): 361 - 368.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. Chen, S. Wang, X. Jia, S. Bajimaya, H. Lin, V. H. Tam, and M. Hu
DISPOSITION OF FLAVONOIDS VIA RECYCLING: COMPARISON OF INTESTINAL VERSUS HEPATIC DISPOSITION
Drug Metab. Dispos., December 1, 2005; 33(12): 1777 - 1784.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
E. J. Jeong, Y. Liu, H. Lin, and M. Hu
SPECIES- AND DISPOSITION MODEL-DEPENDENT METABOLISM OF RALOXIFENE IN GUT AND LIVER: ROLE OF UGT1A10
Drug Metab. Dispos., June 1, 2005; 33(6): 785 - 794.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.